Teva-MedinCell Alliance Heats Up With Second Phase III Trial Underway
Studies Begin For Proposed First Subcutaneous LAI Formulation Of Olanzapine
Teva’s partnership with MedinCell for long-acting injectable products, first penned a decade ago, is beginning to gather steam, as another candidate entered the clinic ahead of a potential first approval in the coming months.
